Repositioning Candidate Details

Candidate ID: R0899
Source ID: DB05911
Source Type: investigational
Compound Type: small molecule
Compound Name: RUS 3108
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
CAS Number: --
Molecular Weight:
DrugBank Indication: Investigated for use/treatment in atherosclerosis.
DrugBank Pharmacology: --
DrugBank MoA: RUS-3108 represents a new approach to the treatment of atherosclerosis. It is a first-in-class compound and works to directly modulate the disease through affecting multiple pathways involved in the disease process such as inflammation, proliferation and thrombosis by inducing a protein called perlecan. It has the potential to prevent the formation of atherosclerotic plaques and reverse atherosclerosis.
Targets: --
Inclusion Criteria: Indication associated